תבנית:תרופה/זיפרקסה 7.5 מ"ג - Zyprexa 7.5 mg
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× |
|
|---|---|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | N05AH Diazepines, oxazepines, thiazepines and oxepines |
| ×ר××× ×¤×¢×× (ATC5) | Â
|
| צ×רת ××ª× | פ××× - PER OS |
| צ×רת ××× ×× | ×××××, TABLETS ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× |
| ×ת×××× | Acute and maintenance treatment of schizophrenia. Zyprexa is indicated for the management of the manifestations of psychotic disorders. Zyprexa is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder. Prevention of recurrence in Bipolar Disorder : In patients whose manic episode has responded to olanzapine treatment Zyprexa is indicated for the prevention of recurrence in patients with Bipolar Disorder. Combination therapy in Bipolar I Disorder: The combination of Zyprexa with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.
|
| ת×× ×ת:× ×ª×× × ×¡×/תר×פ×/×××¤×¨×§×¡× 7.5 ×"× - Zyprexa 7.5 mg | |
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  |
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ×××¤×¨×§×¡× 7.5 ×"× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | - |
|---|---|
| ××××¢ ×רשת | - |
| ×©× ××¦×¨× | LILLY S.A., SPAIN |
| ×©× ××¢× ×ר×ש×× | ELI LILLY ISRAEL LTD |
| ר×ש××× | ת×ר×× ××ש×: 09/2007. ר×ש××× ×ת×ר××: 03/2012 |
| ת×ר×× ×¢×××× ××ר×× | 15/05/19 |
ת××× ×ª ×ר×××
××£ ×× × ×צר ×¢× ××× ××× ×××××ר ת×× ×ת ×¢× ×¤×¨×× ×תר×פ×.
- ××£ ×תר×פ×: ×××¤×¨×§×¡× 7.5 ×"× - Zyprexa 7.5 mg
- ××ר××¡× ××× ×ת ×©× ×¤×¨×× ×תר×פ×: × ××ª× ×ער×× ×ת ××£ ×תר××¤× ××¢××. ×××××× ×××××¤× ×ת:
{{תר×פ×/×××¤×¨×§×¡× 7.5 ×"× - Zyprexa 7.5 mg}}
×:
{{תר×פ×/×××¤×¨×§×¡× 7.5 ×"× - Zyprexa 7.5 mg
| ×©× ×פר××ר=×¢×¨× ××ש (××רס ×ת ××¢×¨× ×©×××× ××××ר)
}}
השינוי האחרון נעשה בֹ־7 באפריל 2023 ב־15:47